Analysis of Routine Blood Profile as Data Supporting for Nursing Assessment in Breast Cancer Patients Undergoing Chemotherapy Treatment at the RSU. Dr. Wahidin Sudirohusodo


Blood Profil
Breast Cancer

How to Cite

SyamY., PrihantonoP., SjattarE. L., & PuspithaA. (2020). Analysis of Routine Blood Profile as Data Supporting for Nursing Assessment in Breast Cancer Patients Undergoing Chemotherapy Treatment at the RSU. Dr. Wahidin Sudirohusodo. Journal of Health Science and Prevention, 3(3S), 136-140.


Chemotherapy is one of the modality therapies given to breast cancer patients to inhibit cancer cell metastases. The side effects of chemotherapy can suppress the hematopoietic system in the bone marrow and progressively affect the patient's prognosis. The aim of study was to analyze routine blood profiles as supporting data in developing nursing care for breast cancer patients undergoing chemotherapy at the RSU. Dr. Wahidin Sudirohusodo Makassar, Indonesia, from June to September 2018. This research was a descriptive research with descriptive survey method. This research was conducted at the RSU Surgical Polyclinic. Dr. Wahidin Sudirohusodo. The sampling technique used was Non-Probability Sampling a purposive sampling method. The participants of this study were patients with breast cancer who undergo chemotherapy treatment with a number of samples that meet the inclusion criteria as many as 32 people. of the 17 routine blood components which were assessed as one of the investigations in 32 patients were found to be 4 abnormal components, red blood cells mean ± SD (3.99 10^6/ uL ± 0.51), hemoglobin mean ± SD (11.18 gr/l ± 1.09), hematocrit mean ± SD (34.96% ± 3.96), and mean ± SD monocyte (15,043 10^3/uL ± 8.95). due to metastasis and side effects of chemotherapy treatment decrease red blood cells, hemoglobin, hematocrit, and increase in specific immune response through increase of monocytes indicator that performing phagocytosis.


1. World Health Organization. 2014 [cited 2019 Feb 14]. Available from;jsessionid=113B0B78133E2D544D5F4D1B27C3AF48?sequence=1

2. Indonesian health profile. 2014. RI Ministry of Health [cited 2019 Feb 14]. Available from

3. Basic health research. 2013. Indonesian health ministry research and development body [cited
2019 Feb 14]. Available from

4. Zhu W, Xu B. Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study. 2015. PLoS ONE 10(8): e0136268. doi:10.1371/ journal.pone.0136268.

5. Barrett-Lee P, Bokemeyer C, Gascón P, NortierJ,Schneider M, Schrijvers D et. al., Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the european cancer anemia survey. 2005. The Oncol 10: 743–57.

6. Hemati S, Jolfaie NA, Abbas Gookizadeh, Rafenia M, Ghavamnasin R. The effects of vitamin E and selenium on cisplatin-induced nephrotoxicity in cancer patients treated with cisplatin-based chemotherapy: A randomized, pacebo-controlled study. 2012. J Res med sci 18(7): 626-7.

7. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91:2214–2221. PMID: 11413508.

8. Boehm DU, Lebrecht A, Schmidt M, Siggelkow W, Lindner C, Litz A, et al. Prognostic impact of haemoglobin levels in breast cancer. Anticancer Res. 2007; 27:1223–1226. PMID: 17465267.

9. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.

10. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.

11. Shibutani M, Maeda K, Nagahara H, et al. The peripheral monocytecount is associated with the density of tumor-associatedmacrophages in the tumor microenvironment of colorectal cancer:a retrospective study. BMC Cancer 2017; 17: 404.

12. Szebeni GJ, Vizler C, Kitajka K, Puskas LG. Inflammation andcancer: extra- andintracellular determinants of tumor-associatedmacrophages as tumor promoters. Mediators Inflamm 2017; 2017: 9294018.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


Download data is not yet available.